Effect of sotagliflozin on albuminuria in patients with type 2 diabetes and chronic kidney disease

Diabetes Obes Metab. 2023 Nov;25(11):3410-3414. doi: 10.1111/dom.15203. Epub 2023 Jul 10.

Authors

David Z I Cherney¹, Deepak L Bhatt², Michael Szarek³, Franklin Sun⁴, Manon Girard⁴, Michael J Davies⁴, Bertram Pitt⁵, Ph Gabriel Steg⁶; SCORED Investigators

Affiliations

¹ University of Toronto, Toronto, Ontario, Canada.
² Mount Sinai Heart, Icahn School of Medicine at Mount Sinai Health System, New York, New York, USA.
³ University of Colorado Anschutz Medical Campus, Aurora, Colorado, USA.
⁴ Lexicon Pharmaceuticals, Inc., The Woodlands, Texas, USA.
⁵ University of Michigan, Ann Arbor, Michigan, USA.
⁶ Université Paris-Cité, AP-HP, Hôpital Bichat, INSERM U-1148, Paris, France.

PMID: 37427762
DOI: 10.1111/dom.15203

No abstract available

Publication types

Research Support, Non-U.S. Gov't

MeSH terms

Albuminuria / drug therapy
Diabetes Mellitus, Type 2* / chemically induced
Diabetes Mellitus, Type 2* / complications
Diabetes Mellitus, Type 2* / drug therapy
Humans
Hypoglycemic Agents / adverse effects
Renal Insufficiency, Chronic* / chemically induced
Renal Insufficiency, Chronic* / complications
Renal Insufficiency, Chronic* / drug therapy

Substances

(2S,3R,4R,5S,6R)-2-(4-chloro-3-(4-ethoxybenzyl)phenyl)-6-(methylthio)tetrahydro-2H-pyran-3,4,5-triol
Hypoglycemic Agents

Grants and funding

CIHR/Canada